Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus ZOVIA 1 35E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus ZOVIA 1 35E 21.
ENSKYCE vs ZOVIA 1/35E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibits ovulation, alters cervical mucus and endometrial lining.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets (if included in the pack) or a 7-day pill-free interval. Each tablet contains ethinyl estradiol 0.035 mg and norethindrone 1 mg.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Norethindrone: 5-12 hours (terminal elimination half-life, approximately 8 hours). Ethinyl estradiol: biphasic with terminal half-life of 10-20 hours (mean 15 hours). Clinical context: Steady state reached in 5-7 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal (approximately 40% as parent drug and metabolites; 20-40% as metabolites; 15-20% as unchanged drug), fecal (30-50% via bile as metabolites), and less than 2% in breast milk.
Category C
Category C
Oral Contraceptive
Oral Contraceptive